Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AChR-mimicking nanobody decoy
- Development stage
- Preclinical
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Peptides
01
Overview
AChR-mimicking nanobody decoy is a computationally designed, non-immunosuppressive therapeutic candidate under development for the treatment of Myasthenia Gravis (MG). It is engineered to mimic the α1-subunit of the acetylcholine receptor (AChR), specifically targeting the Main Immunogenic Region (MIR). By preferentially binding to pathogenic Immunoglobulin G1 (IgG1) autoantibodies, the decoy diverts antibody activity away from native receptors, thereby preventing antibody blocking, antigenic modulation, and complement activation at the neuromuscular junction.
- Other names
- AChR-mimicking nanobody decoysPepenzymespeptide nano enzymes
Beyond the preview
Go deeper on AChR-mimicking nanobody decoy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AChR-mimicking nanobody decoy.